Potent, noncompetitive human CCR2 antagonist; inhibits MCP-1-induced Ca2+ mobilization in hCCR2-CHO cells (IC50 = 13 nM). Exhibits selectivity for CCR2 over CCR1, CCR3-8 and CXCR1-3. Delays onset and reduces neurological signs in an experimental autoimmune encephalomyelitis model of multiple sclerosis in hCCR2 knock-in mice. Orally active.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 379.38. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.64 mL||13.18 mL||26.36 mL|
|5 mM||0.53 mL||2.64 mL||5.27 mL|
|10 mM||0.26 mL||1.32 mL||2.64 mL|
|50 mM||0.05 mL||0.26 mL||0.53 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Buntinx et al (2008) Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor J.Pharmacol.Exp.Ther. 327 1 PMID: 18599682
If you know of a relevant reference for JNJ 27141491, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: JNJ27141491 Chemokine CC Receptors
Citations for JNJ 27141491
Citations are publications that use Tocris products.
Currently there are no citations for JNJ 27141491. Do you know of a great paper that uses JNJ 27141491 from Tocris? If so please let us know.